Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Aug 28

PMID 32849658

Citations 3

Authors

Chunfeng Li

Genhong Cheng

Affiliations

Soon will be listed here.

Abstract

Recent small-scale clinical trials have shown promising results in the use of hydroxychloroquine, an FDA approved anti-malaria drug, for the treatment of COVID-19. However, large scale, randomized and double-blind clinical trials are needed to confirm the safety and efficacy of hydroxychloroquine in COVID-19 patients. Here, we review the progress of using hydroxychloroquine or chloroquine as anti-viral agents, failed clinical trials of chloroquine in treatment of dengue virus and influenza infection, and especially the mechanism of azithromycin in inhibiting viral replication, so as to shed light on the ongoing clinical trials and further researches of hydroxychloroquine on SARS-CoV-2 infected patients.

Citing Articles

Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2.

Liu K, Zou R, Cui W, Li M, Wang X, Dong J ACS Pharmacol Transl Sci. 2021; 3(6):1361-1370.

PMID: 34778724 PMC: 7671100. DOI: 10.1021/acsptsci.0c00163.

HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.

Poloznikov A, Nersisyan S, Hushpulian D, Kazakov E, Tonevitsky A, Kazakov S Front Pharmacol. 2021; 11:621054.

PMID: 33584306 PMC: 7878396. DOI: 10.3389/fphar.2020.621054.

Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review.

Lariccia V, Magi S, Serfilippi T, Toujani M, Gratteri S, Amoroso S J Clin Med. 2020; 9(12).

PMID: 33322733 PMC: 7763517. DOI: 10.3390/jcm9124021.

References

Ray W, Murray K, Hall K, Arbogast P, Stein C . Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366(20):1881-90. PMC: 3374857. DOI: 10.1056/NEJMoa1003833. View

Vigerust D, McCullers J . Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir Viruses. 2009; 1(5-6):189-92. PMC: 4941887. DOI: 10.1111/j.1750-2659.2007.00027.x. View

Dunne M, Singh N, Shukla M, Valecha N, Bhattacharyya P, Dev V . A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis. 2005; 191(10):1582-8. DOI: 10.1086/429343. View

Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L . [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(2):215-219. PMC: 8800713. DOI: 10.3785/j.issn.1008-9292.2020.03.03. View

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Sevestre J . Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020; 34:101663. PMC: 7151271. DOI: 10.1016/j.tmaid.2020.101663. View

INGLOT A . Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol. 1969; 4(2):203-14. DOI: 10.1099/0022-1317-4-2-203. View

Cook J, Randinitis E, Bramson C, Wesche D . Lack of a pharmacokinetic interaction between azithromycin and chloroquine. Am J Trop Med Hyg. 2006; 74(3):407-12. View

Rocha B, Guilarde A, Argolo A, Tassara M, da Silveira L, Junqueira I . Dengue-specific serotype related to clinical severity during the 2012/2013 epidemic in centre of Brazil. Infect Dis Poverty. 2017; 6(1):116. PMC: 5540539. DOI: 10.1186/s40249-017-0328-9. View

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G . Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 382(25):2411-2418. PMC: 7224609. DOI: 10.1056/NEJMoa2012410. View

10.

Li C, Zhu X, Ji X, Quanquin N, Deng Y, Tian M . Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice. EBioMedicine. 2017; 24:189-194. PMC: 5652284. DOI: 10.1016/j.ebiom.2017.09.034. View

11.

Pallister J, Middleton D, Crameri G, Yamada M, Klein R, Hancock T . Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol. 2009; 83(22):11979-82. PMC: 2772715. DOI: 10.1128/JVI.01847-09. View

12.

Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M . In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004; 323(1):264-8. PMC: 7092815. DOI: 10.1016/j.bbrc.2004.08.085. View

13.

Cao B, Parnell L, Diamond M, Mysorekar I . Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med. 2017; 214(8):2303-2313. PMC: 5551583. DOI: 10.1084/jem.20170957. View

14.

Shimizu Y, Yamamoto S, Homma M, Ishida N . Effect of chloroquine on the growth of animal viruses. Arch Gesamte Virusforsch. 1972; 36(1):93-104. DOI: 10.1007/BF01250299. View

15.

Retallack H, Di Lullo E, Arias C, Knopp K, Laurie M, Sandoval-Espinosa C . Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016; 113(50):14408-14413. PMC: 5167169. DOI: 10.1073/pnas.1618029113. View

16.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

17.

Gielen V, Johnston S, Edwards M . Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010; 36(3):646-54. DOI: 10.1183/09031936.00095809. View

18.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

19.

Tan Y, Yam W, Sun J, Chu J . An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease. Antiviral Res. 2017; 149:143-149. DOI: 10.1016/j.antiviral.2017.11.017. View

20.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View